Biotie Therapies Corp. (“Biotie” or the “Company”) has conveyed Biotie shares held as treasury shares, that were issued on 17 December 2014, pursuant to the Stock Option Plan 2011 and the Equity Incentive Plan 2011 (the “Plans”), as follows:
| Shares conveyed | Cumulative shares conveyed since 17 December 2014 | Remaining shares to be conveyed |
| 1,009,375 | 1,009,375 | 1,438,000 |
Under the Stock Option Plan 2011, the owners of the stock options may subscribe for a maximum total of 7,401,000 new shares in the Company or existing shares held by the Company, of which a total of 1,844,250 were subscribed for in 2014. A total of 942,500 shares have been subscribed for during the period 17 December 2014 and 19 January 2015 and 942,500 of the treasury shares will be used for these share subscriptions. The subscription price of EUR 0.01 per share has been fully paid by the employee and the EUR 9,425 funds received will be credited to the Company’s reserve for non-restricted equity. Due to share issues already made pursuant to the Stock Option Plan 2011, forfeitures and some of the instruments based on the plan having been left unallocated, a maximum of 3,080,500 shares may still be issued pursuant to the Stock Option Plan 2011.
The second vesting period of the Equity Incentive Plan 2011 ended on 5 January 2015, after which the Company’s shares shall be delivered to employees on the basis of the granted share units. It was resolved pursuant to the authorization of the Annual General Meeting of the Shareholders held on 3 April 2014 to issue 66,875 existing treasury shares to the employees without consideration for the purposes of remunerating the employees pursuant to the terms and conditions of the Equity Incentive Plan 2011 and thus, there is an especially weighty financial reason to derogate from the pre-emptive right of the shareholders, as referred to in Chapter 9 Section 4(1) of the Companies Act (624/2006, as amended). Due to share issues already made pursuant to the Equity Incentive Plan 2011, forfeitures and some of the instruments based on the plan having been left unallocated, a maximum of 1,382,500 shares may still be issued pursuant to the Equity Incentive Plan 2011.
| Increase in number of outstanding shares | Total amount of voting rights | Number of the Company’s shares held by the Group | Total number of registered shares |
| 1,009,375 | 451,705,390 | 4,262,784 | 455,968,174 |
Turku, 20 January 2015
Biotie Therapies Corp.
Timo Veromaa, President and CEO
For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com
www.biotie.com
Help employers find you! Check out all the jobs and post your resume.
